BioNTech
NEWS
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
Life Science industries are seeing massive financial fluctuations in how they’re handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here’s a look at that story and more COVID-19 news.
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
Pfizer reported first-quarter revenues of $25.7 billion, a whopping 82% operational growth. This growth was largely driven by its COVID-19 vaccine developed with BioNTech and its antiviral drug, Paxlovid.
Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
JOBS
IN THE PRESS